Cell-Immune Pharma (CIP)

Engineering Human-Derived T-Cell Solutions to Supercharge Vaccines & Immunotherapies

$10-15B	100 s	>90%	C$2M Cap	Location: Montréal, QC
Global RNA therapies	Epitopes / month	HLA population reach	Seed safe round	Founded: August 2022

BUSINESS MODEL & EXIT STRATEGY

CIP is pursuing licensing and co-development opportunities with RNA and vaccine partners.

Early agreements could generate $6–12M in upfront and milestone payments by 2027–28, with royalties from future commercial products.

Collaboration with HDT Bio (CQDM program) and early engagement with Sanofi and Daiichi Sankyo highlight industry alignment around T-cell–enhanced vaccine design.

NEXT MILESTONES (Q1 2026 – Q1 2027)

2026

- **Q3** — **Complete CMV epitope mapping**
- **Q4** — **Finalize cassette** for preclinical validation

2027

- **Q1** — **First partner demo with HDT Bio** validating clinical integration (GBMprogram)
- **Q3** — **Expand platform to second indication** and initiate preclinical validation

THE PROBLEM

Most current vaccines and immunotherapies stimulate antibodies only, leaving out the immune system's most powerful defense: T-cells.

Without robust T-cell activation, protection fades, viral reactivation occurs, and cancers remain "invisible" to the immune system.

This gap is critical in transplant patients, hard-to-treat cancers and emerging infections.

OUR SOLUTION

CIP's human PBMC platform identifies natural T-cell targets and converts them into compact, manufacturable immune modules.

These have been shown to drive strong, balanced T-cell activation—a key predictor of durable protection and therapeutic response—and can be rapidly adapted across multiple pathogens.

PROVEN PLATFORM

Human-validated workflow demonstrates compact multi-epitope, multi-HLA constructs that drive strong, balanced T-cell activation while maintaining safety.

The platform can screen hundreds of epitopes monthly across multiple HLA types and is ready to power discovery of new immune targets such as CMV, enabling rapid expansion to multiple targets.

$10–15B GLOBAL CMV MARKET

$2B: Transplants | **$5B:** Oncology | **$5–10B:** Congenital

CIP is uniquely positioned to solve CMV's core challenge, restoring durable T-cell immunity where antibody vaccines fail. The CMV program serves as the first validation use-case for the platform—de-risking expansion to other viral and pathogen-linked oncology applications.

COMPETITIVE LANDSCAPE

Company	Focus	Limitation	CIP Advantage
Moderna	Antibody-based CMV vaccine	Limited T-cell	Human-validated T-cell targets
Hookipa Biotech	Viral-vector CMV vaccine	Narrow HLA coverage	>90% HLA population reach
CIP	**T-cell platform**	**Early stage**	**Multi-pathogen potential**

INVESTMENT OPPORTUNITY

This seed round funds completion of the CMV discovery program and positions CIP for its first licensing deal within 24 months, establishing early nondilutive revenue and validating the platform's commercial model.

- **Seed SAFE @ C$2M cap (+25% discount)**
- **$500K open** to complete $1.3M round
- **$800K secured** from angels and grants (VRQ, CQDM, Axelys)
- **24-month runway** to first licensing revenue and IP-driven exit

CIP Seed Round Goal:
Launch a high-throughput, human-validated T-cell discovery engine targeting pathogen and pathogen-linked cancers, driving CMV completion and first licensing within 24 months.

TEAM

David Lapointe, CEO
Biotech CEO | $50M+ raised
Global BD track record

Dr. Réjean Lapointe, CSO
Director, CRCHUM Cancer Research
25 yrs T-cell immunology

Dr. Jean-François Cailhier, Chief Medical Officer
Clinician-scientist
Transplant & inflammation

Pôle ARENA du Québec
invest@arenapole.ca
axelys
axelys.ca